Vilacto Bio Inc. (OTCMKTS:ZFLOD) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement

On April 19, 2017, we entered into a Stock Purchase Agreement
(the Agreement) with Pharma GP APS, a Denmark corporation (Pharma
GP) and its sole shareholder, 9 Heroes APS, a Denmark
corporation. In accordance with the terms of the Agreement, we
will purchase all of the outstanding shares of Pharma GP for the
purchase price (the Purchase Price) of $6,000,000.00, payable as
$3,000,000.00 in cash and the balance in shares of our common
stock.

The closing of the above transactions is expected to occur on May
31, 2017 (the Closing Date). The Agreement is conditioned on our
paying the Purchase Price, obtaining financing in the amount of
$4,000,000.00 for operational expenses, and receiving audited
financial statements from Pharma GP, among other conditions as
contained in the Agreement.

We currently do not have the money on hand to pay the Purchase
Price, and we must obtain additional financing to meet the
conditions to close the transaction.

The Agreement includes customary representations, warranties and
covenants among the parties to each other as of specific dates.

The foregoing description of the Agreement is qualified in its
entirety by reference to the full text of the Agreement, which is
included as an exhibit to this Current Report on Form 8-K and is
incorporated by reference herein.

Pharma GP is a manufacturer of skincare products with
distribution in several countries. The companys body and facial
creams are designed for moisturizing, skin regeneration, wound
healing and a variety of skin issues, such as dry and cracked
skin, among other things.

In addition, Pharma GP owns patents, trademarks and production
facilities for an ingredient designed to be used in
pharmaceuticals and medical devices for treating a wide range of
issues. Pharma GP currently has skincare products that are
available over the counter. However, the company intends to
develop, market and sell pharmaceutical skincare products to
treat various ailments using its patented technology. Currently,
the company has no government approved products, but with the
financing, we intend to purchase Pharma GP and focus on those
clinical applications. We expect to have more information on the
status of the Closing of the Agreement and our new business
direction in future filings.

Section 9 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

About Vilacto Bio Inc. (OTCMKTS:ZFLOD)

Vilacto Bio Inc., formerly Zlato Inc., is engaged in the development and sale of electronic medical record (EMR) software for small and medium sized physician offices and clinics. Its basic EMR software collects and captures patient data electronically, and stores it in a format that enables access, viewing and distribution by printing or e-mail. Its planned second phase product development will focus on interconnectivity of its EMR software with various third-party vital signs monitors, such as blood pressure monitors or temperature monitors. Its basic EMR software has been developed to provide online, real time computer access, and contains a physician/medical personnel interface and an electronic database backend, which collects and organizes all patient data. Its EMR database is backed up instantly when data is entered. The backup facilities can either be managed in house on separate servers or with independent third-party data storage facilities.

Vilacto Bio Inc. (OTCMKTS:ZFLOD) Recent Trading Information

Vilacto Bio Inc. (OTCMKTS:ZFLOD) closed its last trading session at 0.0000 with shares trading hands.